September 2010
Worldwide Biotech;Sep2010, Vol. 22 Issue 9, p3
Trade Publication
The article reports on the European Medicines Agency (EMA) Committee for Orphan Medical Products' adoption of a positive opinion and recommendation of the granting of orphan medicinal product designation for XOMA Ltd.'s XOMA 052, an antibody to interleukin-1 beta, to treat Behcet's disease. The designation's provision of European Union (EU) market exclusivity for the given indication is discussed. A study of Behcet's disease patients with uveitis showed that XOMA 052 reduced intraocular inflammation and improved visual acuity.


Related Articles

  • XOMA Inks $505M Servier Pact for IL-1 Inhibitor XOMA 052. Boggs, Jennifer // BioWorld Today;1/5/2011, Vol. 22 Issue 3, p1 

    The article reports on a structured ex-U.S. contract signed by XOMA Ltd. with Les Laboratoires Servier for interleukin-1 inhibitor XOMA 052. Experts believe that the partnership came ahead of the majority of expectations, since Phase II study results in Type II diabetes are not yet available....

  • IL-1 Blockers Gain Momentum As XOMA Partners Lead Drug. Morrison, Trista // BioWorld Insight;1/10/2011, Vol. 19 Issue 2, p3 

    The article discusses the potentials of the use of interleukin-1 (IL-1) inhibitor to treat autoimmune and inflammatory diseases such as rheumatoid arthritis. Because of the potentials of the IL-1, XOMA Ltd. focused its interest in XOMA 052 antibody which binds to the inhibitor to treat other...

  • XOMA Inks $505M Servier Pact for IL-1 Inhibitor.  // Bioworld Week;1/10/2011, Vol. 19 Issue 2, p1 

    The article reports on the 35 million dollars up front deal by XOMA Ltd. with Les Laboratories Servier for its interleukin-1 inhibitor XOMA 052. It notes that the partnership will focus first on the treatment of Behcet's uveitis, a debilitating ophthalmic inflammatory condition. Steven B. Engle,...

  • Parents for Orphans. O'Donnell, Peter // Applied Clinical Trials;May2002, Vol. 11 Issue 5, p34 

    Focuses on a guideline on the requirements for submission of application for a proposed orphan drug in the European Union. Revisions in the format and content of applications for designation of orphan products; Improvements in the marketing of medicinal product; Prevalence of a condition for...

  • Importance of serum amyloid-A in Behçet's disease. Agilli, Mehmet; Aydin, Fevzi; Kurt, Yasemin; Cayci, Tuncer // Clinical Rheumatology;Feb2016, Vol. 35 Issue 2, p551 

    No abstract available.

  • Copy number variations and gene polymorphisms of Complement components in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome. Xu, Dengfeng; Hou, Shengping; Zhang, Jun; Jiang, Yanni; Kijlstra, Aize; Yang, Peizeng // Scientific Reports;8/14/2015, p12989 

    Complement is involved in many immune-mediated diseases. However, the association of its copy number variations (CNVs) and polymorphisms with Behcet's disease (BD) and Vogt-Koyanagi-Harada syndrome (VKH) is unknown. We examined copy number and mRNA expression by real-time PCR. Cytokine...

  • Decisions Update.  // PharmaWatch: Biotechnology;July 2005, Vol. 4 Issue 7, p11 

    The article reports that Canada-based biotech firm Lorus Therapeutics Inc. has been granted orphan drug status in the EU for its lead pancreatic cancer treatment Virulizin. The drug already holds orphan status in the U.S. Lorus believes this endorsement indicates that the product has the...

  • Introducing the immunomodulatory effects of mesenchymal stem cells in an experimental model of Behçet’s disease. Mazaheri, Tina; Esmaeilzadeh, Abdolreza; Mirzaei, Mehri H.KH. // Journal of Medical Hypotheses & Ideas;Jan2012, Vol. 6 Issue 1, p23 

    Behçet’s disease (BD) is a systemic vasculitis which is characterised by oral, aphthous ulcers, genital ulcers, skin lesions and ocular manifestations. Although the aetiopathogenesis of BD is still unknown, the critical role of Th1 immune responses, neutrophil hyperactivation alongside...

  • Financings Roundup.  // BioWorld Today;6/8/2009, Vol. 20 Issue 108, p4 

    This article reveals the plan of XOMA Ltd. to raise $12 million in its second financing deal in less than a month. Particular focus is given to the terms of the agreement signed between XOMA and certain institutional investors. There is a plan to use proceeds from the financing deal to support...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics